TScan: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease

Grants and Contracts Details

StatusActive
Effective start/end date12/15/221/8/25

Funding

  • TScan Therapeutics: $121,079.00